PDCD1 and neoplasm: Previous studies have shown that the expression status of PD-1/PD-L1 in tumours is associated with treatment responses and clinical outcomes following PD-1/PD-L1 pathway inhibition13–21 and can be used as a biomarker for predicting the effectiveness of ICI treatment22,23.